New number of shares and votes in Moberg Pharma AB (publ)

STOCKHOLM, June 29th, 2018, Moberg Pharma AB (OMX: MOB) announced that the total number of common shares in the company has increased to 17,703,762. The 263,000 newly issued shares are held by the company to secure its commitments under incentive programmes.

As per 29 June 2018, the total number of shares in Moberg Pharma AB (publ) amounts to 17,703,762. All shares are common shares. The total number of votes are 17,703,762. The increase in the number of shares and votes results from an issue of 263,000 class C shares. The newly issued class C shares have been repurchased and, by virtue of the conversion clause in the articles of association, converted to common shares. As per 29 June 2018 the company holds 263,000 common shares. The shares are intended to ensure fulfilment of commitments under incentive programmes.

About this information
The above information has been made public in accordance with the Swedish Financial Instruments Trading Act. The information was released for public distribution on 29 June 2019 at 8:00 am CET.

For additional information, please contact:
Peter Wolpert, CEO, telephone: +1 908 432 22 03 (US), +46 70 735 71 35, e-mail: peter.wolpert@mobergpharma.se
Mark Beveridge, VP Finance, telephone: 076 - 805 82 88, e-mail: mark.beveridge@mobergpharma.se

About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ.) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 30 countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, New Skin®, Dermoplast®and Domeboro®. Kerasal Nail®(Emtrix®, Zanmira®or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two assets in late-stage clinical development, MOB-015 (onychomycosis, phase 3 studies ongoing) and BUPI (pain management in oral mucositis, preparations for phase 3 studies ongoing). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).

Tags:

About Us

Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s main asset, MOB-015, is a novel topical treatment for onychomycosis, for which phase 3 data in more than 800 patients is expected in late 2019 in North America and the first half of 2020 in Europe. The pipeline also includes the late-stage asset BUPI for pain relief in oral mucositis. Clinical data generated for both assets indicate they have the potential to become market leaders in their respective niches. Moberg Pharma is headquartered in Stockholm and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).

Contacts